ANGO News and Press, AngioDynamics Inc. From 04/07/22

The shares AngioDynamics (NASDAQ:ANGO) are trading sharply higher in the morning hours Thursday after the medical device maker reported better than expected earnings for 3Q FY22 and kept its guidance for the full year unchanged in line with the consensus. However, the top line missed the...

AngioDynamics press release (NASDAQ:ANGO): Q3 Non-GAAP EPS of $0.03 beats by $0.04. Revenue of $73.97M (+3.9% Y/Y) misses by $2.35M. FY22 Outlook: The Company continues to expect fiscal year 2022 net sales to be in the range of $310 to $315 million vs consensus of $313.66M; Gross margin to be...

Fiscal 2022 Third Quarter Highlights Net sales of $74.0 million increased 3.9% compared to the prior-year quarter Med Tech grew 28.6% and Med Device declined 2.8% year over year Gross margin of 52.2% declined 190 basis points year over year GAAP l...

AngioDynamics (NASDAQ:ANGO) is scheduled to announce FQ3 earnings results on Thursday, April 7th, before market open. The consensus EPS Estimate is -$0.01 and the consensus Revenue Estimate is $76.32M (+7.2% Y/Y). Over the last 2 years, ANGO has beaten EPS estimates 75% of the time and h...

The following slide deck was published by AngioDynamics, Inc. in conjunction with this event. For further details see: AngioDynamics (ANGO) presents at KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum - Slideshow

The following slide deck was published by AngioDynamics, Inc. in conjunction with this event. For further details see: AngioDynamics (ANGO) presents at Barclays Healthcare Conference - Slideshow

AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that it will report financial results for the third quarter of fiscal year 2022 before the market open...

AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice Presid...

Penumbra has been posting strong revenue growth numbers, but the Street has not been rewarding the shares. The company still has not recovered the share it lost in stroke due to a product recall, but growth is accelerating and the Thunderbolt launch could drive a bigger shift. The...

The following slide deck was published by AngioDynamics, Inc. in conjunction with this event. For further details see: AngioDynamics (ANGO) Presents At BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference - Slideshow